Polycystic ovaries – beyond menopause

References

• Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011;7:219–31
   PubMed Web of Science ®Google Scholar
• Zawadski J, Dunaif AGJ. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Dunaif AGJ, Haseltine FP, Merriam GR, eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific publications, 1992:377–84
   Google Scholar
• Azziz R. PCOS: a diagnostic challenge. Reprod Biomed Online 2004;8:644–8
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456–88
   PubMed Web of Science ®Google Scholar
• Khan KA, Stas S, Kurukulasuriya LR. Polycystic ovarian syndrome. J Cardiometab Syndr 2006;1:125–30
   PubMedGoogle Scholar
• Botwood N, Hamilton-Fairley D, Kiddy D, Robinson S, Franks S. Sex hormone-binding globulin and female reproductive function. J Steroid Biochem Mol Biol 1995;53:529–31
   PubMed Web of Science ®Google Scholar
• Holte J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab 1996;10:221–4
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004;82:661–5
   PubMed Web of Science ®Google Scholar
• DeUgarte CM, Bartolucci AA, Azziz R, et al. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005;83:1454–60
   PubMed Web of Science ®Google Scholar
• Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16:347–63
   PubMed Web of Science ®Google Scholar
• Fletcher B, Gulanick M, Lamendola C. Risk factors for type 2 diabetes mellitus. J Cardiovasc Nurs 2002;16:17–23
   PubMedGoogle Scholar
• Vrbikova J, Hainer V. Obesity and polycystic ovary syndrome. Obes Facts 2009;2:26–35
   PubMed Web of Science ®Google Scholar
• Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 2006;113:1203–9
   PubMed Web of Science ®Google Scholar
• Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011;95:1073–9.e1–11
   PubMed Web of Science ®Google Scholar
• Fauser BCJM, Tarlatzis BC, Rebar RW, et al.Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97:28–38.e25
   PubMed Web of Science ®Google Scholar
• Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113–32
   PubMed Web of Science ®Google Scholar
• García-Romero G, Escobar-Morreale HF. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus. Curr Diabetes Rev 2006;2:39–49
   PubMedGoogle Scholar
• Mehrabian F, Khani B, Kelishadi R, Kermani N. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci 2011;16: 763–9
   PubMed Web of Science ®Google Scholar
• Hudecova M, Holte J, Olovsson M, et al. Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up. Fertil Steril 2011;96:1271–4
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic. I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009;4:113–19
   PubMedGoogle Scholar
• Duleba AJ, Dokras A. Is PCOS an inflammatory process?Fertil Steril 2012;97:7–12
   PubMed Web of Science ®Google Scholar
• de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update 2011;17:495–500
   PubMed Web of Science ®Google Scholar
• Soares GM, Vieira CS, Martins WP, et al. Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome?Clin Endocrinol (Oxf) 2009;71:406–11
   PubMed Web of Science ®Google Scholar
• Davis SR, Castelo-Branco C, Chedraui P, et al. Understanding weight gain at menopause. Climacteric 2012;15:419–29
   PubMed Web of Science ®Google Scholar
• Tchernof A, Poehlman ET, Després JP. Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes Metab 2000;26:12–20
   PubMed Web of Science ®Google Scholar
• Toth MJ, Tchernof A, Sites CK, Poehlman ET. Menopause- related changes in body fat distribution. Ann N Y Acad Sci 2000;904:502–6
   PubMed Web of Science ®Google Scholar
• Lovejoy JC. The menopause and obesity. Prim Care 2003;30: 317–25
   PubMed Web of Science ®Google Scholar
• Lobo RA. Metabolic syndrome after menopause and the role of hormones. Maturitas 2008;60:10–18.
   PubMed Web of Science ®Google Scholar
• Dong M, Ren J. What fans the fire: insights into mechanisms of leptin in metabolic syndrome-associated heart diseases. Curr Pharm Des 2013 May 14. Abstract 1. Epub ahead of print
   Web of Science ®Google Scholar
• Singh AK, Tiwari S, Gupta A, Natu SM, Mittal B, Pant AB. Association of resistin with metabolic syndrome in Indian subjects. Metab Syndr Relat Disord 2012;10:286–91
   PubMed Web of Science ®Google Scholar
• Izadi V, Farabad E, Azadbakht L. Epidemiologic evidence on serum adiponectin level and lipid profile. Int J Prev Med 2013;4:133–40
   PubMedGoogle Scholar
• Lee SW, Jo HH, Kim MR, You YO, Kim JH. Association between metabolic syndrome and serum leptin levels in postmenopausal women. J Obstet Gynaecol2012;32:73–7
   PubMedGoogle Scholar
• Toulis KA, Goulis DG, Farmakiotis D, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009;15:297–307
   PubMed Web of Science ®Google Scholar
• Krentz AJ, von Mühlen D, Barrett-Connor E. Adipocytokine profiles in a putative novel postmenopausal polycystic ovary syndrome (PCOS) phenotype parallel those in premenopausal PCOS: the Rancho Bernardo Study. Metabolism 2012;61: 1238–41
   PubMed Web of Science ®Google Scholar
• Markopoulos MC, Valsamakis G, Kouskouni E, et al. Study of carbohydrate metabolism indices and adipocytokine profile and their relationship with androgens in polycystic ovary syndrome after menopause. Eur J Endocrinol 2012;168:83–90
   PubMed Web of Science ®Google Scholar
• Chae CU, Derby CA. The menopausal transition and cardiovascular risk. Obstet Gynecol Clin North Am 2011;38:477–88
   PubMed Web of Science ®Google Scholar
• Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?J Am Coll Cardiol 2009;54:2366–73
   PubMed Web of Science ®Google Scholar
• Lima R, Wofford M, Reckelhoff JF. Hypertension in postmenopausal women. Curr Hypertens Rep 2012;14:254–60
   PubMed Web of Science ®Google Scholar
• Do KA, Green A, Guthrie JR, Dudley EC, Burger HG, Dennerstein L. Longitudinal study of risk factors for coronary heart disease across the menopausal transition. Am J Epidemiol 2000;151:584–93
   PubMed Web of Science ®Google Scholar
• Yanes LL, Reckelhoff JF. Postmenopausal hypertension. Am J Hypertens 2011;24:740–9
   PubMed Web of Science ®Google Scholar
• Kim C, Edelstein SL, Crandall JP, et al.; Diabetes Prevention Program Research Group. Menopause and risk of diabetes in the Diabetes Prevention Program. Menopause 2011;18:857–68
   PubMed Web of Science ®Google Scholar
• Kim C. Does menopause increase diabetes risk? Strategies for diabetes prevention in midlife women. Womens Health (Lond Engl) 2012;8:155–67
   PubMedGoogle Scholar
• Polotsky HN, Polotsky AJ. Metabolic implications of menopause. Semin Reprod Med 2010;28:426–34
   PubMed Web of Science ®Google Scholar
• Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. Arch Intern Med 2008; 168:1568–75
   PubMed Web of Science ®Google Scholar
• Moreau KL, Hildreth KL, Meditz AL, Deane KD, Kohrt WM. Endothelial function is impaired across the stages of the menopause transition in healthy women. J Clin Endocrinol Metab 2012;97:4692–700
   PubMed Web of Science ®Google Scholar
• Brown ZA, Louwers YV, Fong SL, et al. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertil Steril 2011;96:1259–65
   PubMed Web of Science ®Google Scholar
• Krentz AJ, von MD, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 2007;14:284–92
   PubMed Web of Science ®Google Scholar
• Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93: 1276–84
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K, Spinas G, Rini GB, Carmina E. Long-term consequences of polycystic ovary syndrome on cardiovascular risk. Fertil Steril 2009;91(4 Suppl):1563–7
   PubMed Web of Science ®Google Scholar
• Markopoulos MC, Rizos D, Valsamakis G, et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab 2011;96:623–31
   PubMed Web of Science ®Google Scholar
• Puurunen J, Piltonen T, Morin-Papunen L, et al. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab 2011;96:1827–34.
   PubMed Web of Science ®Google Scholar
• Puurunen J, Piltonen T, Jaakkola P, Ruokonen A, Morin-Papunen L, Tapanainen JS. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:1973–8
   PubMed Web of Science ®Google Scholar
• Gambineri A, Patton L, Altieri P, et al. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-termprospective study. Diabetes 2012;61:2369–74
   PubMed Web of Science ®Google Scholar
• Cobin RH. Polycystic ovarian syndrome and insulin resistance: implications for estrogen use in premenopausal and postmenopausal women. Metab Syndr Relat Disord 2005; 3:259–69
   PubMedGoogle Scholar
• Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab 2011;96:3794–803
   PubMed Web of Science ®Google Scholar
• Hudecova M, Jan H, Christian B, Poromaa Inger S. Long-term reproductive and metabolic consequences of PCOS. Curr Diabetes Rev 2012;8:444–51
   PubMedGoogle Scholar
• Margolin E, Zhornitzki T, Kopernik G, Kogan S, Schattner A, Knobler H. Polycystic ovary syndrome in post-menopausal women – marker of the metabolic syndrome. Maturitas 2005;50:331–6
   PubMed Web of Science ®Google Scholar
• Ireland K, Child T. Polycystic ovary syndrome and the postmenopausal woman. J Br Menopause Soc 2006;12:143–8
   PubMedGoogle Scholar
• Lambrinoudaki I. Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. Maturitas 2011; 68:13–16
   PubMed Web of Science ®Google Scholar
• Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785–9
   PubMed Web of Science ®Google Scholar
• Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87:2013–17
   PubMed Web of Science ®Google Scholar
• Carmina E. Cardiovascular risk and events in polycystic ovary syndrome. Climacteric 2009;12(Suppl 1):22–5
   PubMedGoogle Scholar
• Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long- term follow-up. J Clin Epidemiol 1998;51:581–6
   PubMed Web of Science ®Google Scholar
• Toulis KA, Goulis DG, Mintziori G, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011;17:741–60
   PubMed Web of Science ®Google Scholar
• Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 2013;19:268–88
   PubMed Web of Science ®Google Scholar
• Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009;19:398–405
   PubMed Web of Science ®Google Scholar
• Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012;27:1327–31
   PubMed Web of Science ®Google Scholar